Cytokine response in inflammatory myopathies

Current Rheumatology Reports

Volumn 9, Issue 4, 2007, Pages 286-290

  Tournadre, Anne ^b   Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; CELL DIFFERENTIATION; CELL MIGRATION; CELLULAR STRESS RESPONSE; CYTOKINE RESPONSIVE ELEMENT; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INFLAMMATORY CELL; MUSCLE BLOOD FLOW; MUSCLE CELL; MUSCLE STRENGTH; PATHOPHYSIOLOGY; POLYMYOSITIS; REVIEW; VASCULAR DISEASE;

EID: 34547915977     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0046-6     Document Type: Review

References (45)

1. Emslie-Smith AM, Arahata K, Engel AG: Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989, 20:224-231.
2. Bartocionni E, Gallucci S, Scuderi F, et al.: MHC class I, MHC class II and intercellular adhesion molecule-1 expression in inflammatory myopathies. Clin Exp Immunol 1994, 95:166-172.
3. Hoogendijk JE, Amato AA, Lecky BR, et al.: 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. Neuromuscular Disorders 2004, 14:337-345.
4. Page G, Chevrel G, Miossec P: Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004, 50:199-208. This study reports the presence of both immature and mature DCs, the expression of IL-17, IFN-γ, and chemokines, and associated receptors in inflammatory myopathy biopsies, supporting interactions among DCs, T cells, and chemokines.
5. Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
6. Lundberg I, Ulfgren AK, Nyberg P, et al.: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:865-874.
7. Lepidi H, Frances V, Figarella-Branger D, et al.: Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998, 24:73-79.
8. Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996, 55:342-347.
9. De Bleecker JL, Meire VI, Declercq W, Van Aken EH: Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999, 9:239-246.
10. Grundtman C, Salomonsson S, Dorph C, et al.: Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007, 56:674-687.
11. Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995, 63:9-16.
12. Adams EM, Kirkley J, Eidelman G, et al.: The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997, 109:275-285.
13. Harrington LE, Hatton RD, Mangan PR, et al.: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. Along with the study by Park et al. [14•], this study favors the idea of a distinct effector lineage called Th17.
14. Park H, Li Z, Yang XO, et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141. In addition to the above study by Harrington et al. [13•], this study favors the idea of a distinct effector lineage called Th17.
15. Miossec P: Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003, 48:594-601.
16. Chabaud M, Fossiez F, Taupin JL, Miossec P: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998, 161:409-414.
17. Chevrel G, Page G, Granet C, et al.: Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003, 137:125-133.
18. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC: Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000, 94:99-104.
19. Gallucci S, Provenzano C, Mazzarelli P, et al.: Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol 1998, 10:267-273.
20. Nagaraju K, Raben N, Merritt G, et al.: A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998, 113:407-414.
21. Chevrel G, Granet C, Miossec P: Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005, 64:1257-1262.
22. Jo C, Kim H, Jo I, et al.: Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Biochim Biophys Acta 2005, 1743:187-197.
23. Ebisui C, Tsujinaka T, Morimoto T, et al.: Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond) 1995, 89:431-439.
24. Austin L, Burgess AW: Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J Neurol Sci 1991, 101:193-197.
25. Langen RC, van der Velden JL, Schols AM, et al.: Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 2004, 18:227-237.
26. De Rossi M, Bernasconi P, Baggi F, et al.: Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000, 12:1329-1335.
27. Nagaraju K, Raben N, Loeffler L, et al.: Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000, 97:9209-9214.
28. Lundberg I, Ulfgren AK, Nyberg P, et al.: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:865-874.
29. Nyberg P, Wikman AL, Nennesmo I, Lundberg I: Increased expression of interleukin lalpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000, 27:940-948.
30. Shreeniwas R, Koga S, Karakurum M: Hypoxia-mediated induction of endothelial cell interleukine-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Investigation 1992, 90:2333-2339.
31. De Bleecker JL, Engel AG: Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994, 53:369-376.
32. Nagaraju K, Rider LG, Fan C, et al.: Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006, 3:2.
33. Civatte M, Bartoli C, Schleinitz N, et al.: Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005, 31:70-79.
34. Casciola-Rosen L, Nagaraju K, Plotz P, et al.: Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005, 201:591-601. This article reports the preferential expression of myositis autoantigens in regenerating muscle cells implicating regenerating muscle as potential source of autoantigens.
35. Howard OM, Dong HF, Yang D, et al.: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002, 196:781-791.
36. Levine SM, Rosen A, Casciola-Rosen LA: Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2003, 15:708-713.
37. Nagaraju K, Casciola-Rosen L, Lundberg I, et al.: Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005, 52:1824-1835. This article addresses the role of MHC class I overexpression and endoplasmic reticulum stress response in myositis pathogenesis.
38. Wiendl H, Hohlfeld R, Kieseier BC: Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005, 26:373-380. A detailed and informative review on the immunopathogenesis of inflammatory myopathies.
39. Iannone F, Scioscia C, Falappone PC, et al.: Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006, 33:1802-1804.
40. Efthimiou P, Schwartzman S, Kagen LJ: Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006, 65:1233-1236.
41. Chabaud M, Page G, Miossec P: Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001, 167:6015-6020.
42. Noss EH, Hausner-Sypek DL, Weinblatt ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021-1026.
43. Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601-607.
44. Kremer JM, Dougados M, Emery P, et al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:2263-2271.
45. Nagaraju K, Raben N, Villalba ML, et al.: Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999, 92:161-169.